Hanseatic Management Services Inc Ionis Pharmaceuticals Inc Transaction History

Hanseatic Management Services Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	SELL	$37.12 - $46.52 $6,755 - $8,466	-182 Reduced 1.66%	10,811 $408,000
Q3 2022 Nov 08, 2022	SELL	$36.54 - $48.66 $8,367 - $11,143	-229 Reduced 2.04%	10,993 $486,000
Q2 2022 Aug 05, 2022	BUY	$31.71 - $43.0 $355,849 - $482,546	11,222 New	11,222 $415,000
Q4 2019 Jan 29, 2020	SELL	$53.85 - $65.27 $447,708 - $542,654	-8,314 Closed	0 $0
Q2 2019 Jul 19, 2019	SELL	$62.09 - $86.14 $19,558 - $27,134	-315 Reduced 3.65%	8,314 $534,000
Q1 2019 May 08, 2019	BUY	$52.92 - $81.17 $25,877 - $39,692	489 Added 6.01%	8,629 $700,000
Q4 2018 Jan 29, 2019	BUY	$43.37 - $59.54 $353,031 - $484,655	8,140 New	8,140 $440,000
Q2 2018 Aug 14, 2018	SELL	$40.53 - $50.7 $27,074 - $33,867	-668 Closed	0 $0
Q1 2018 May 02, 2018	SELL	$44.08 - $55.05 $153,662 - $191,904	-3,486 Reduced 83.92%	668 $29,000
Q4 2017 Feb 14, 2018	BUY	$50.3 - $64.39 $60,863 - $77,911	1,210 Added 41.1%	4,154 $209,000
Q3 2017 Nov 07, 2017	SELL	$45.56 - $59.57 $24,465 - $31,989	-537 Reduced 15.43%	2,944 $149,000
Q2 2017 Aug 11, 2017	BUY	N/A	3,481	3,481 $177,000

389

125M

2.25M

510K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.64B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Hanseatic Management Services Inc, based on Form 13F filings with the SEC.

Stay updated on Hanseatic Management Services Inc with notifications on news.